NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
These approvals mark significant progress for Venus Remedies in expanding its market presence
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Subscribe To Our Newsletter & Stay Updated
